224 related articles for article (PubMed ID: 22790872)
1. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.
Nikulenkov F; Spinnler C; Li H; Tonelli C; Shi Y; Turunen M; Kivioja T; Ignatiev I; Kel A; Taipale J; Selivanova G
Cell Death Differ; 2012 Dec; 19(12):1992-2002. PubMed ID: 22790872
[TBL] [Abstract][Full Text] [Related]
2. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.
Li J; Tan M; Li L; Pamarthy D; Lawrence TS; Sun Y
Neoplasia; 2005 Apr; 7(4):312-23. PubMed ID: 15967108
[TBL] [Abstract][Full Text] [Related]
3. Chk2 mediates RITA-induced apoptosis.
de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
[TBL] [Abstract][Full Text] [Related]
4. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
5. Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter.
Nabilsi NH; Ryder DJ; Peraza-Penton AC; Poudyal R; Loose DS; Kladde MP
J Biol Chem; 2013 Dec; 288(50):35940-51. PubMed ID: 24163369
[TBL] [Abstract][Full Text] [Related]
6. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
7. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis.
Kho PS; Wang Z; Zhuang L; Li Y; Chew JL; Ng HH; Liu ET; Yu Q
J Biol Chem; 2004 May; 279(20):21183-92. PubMed ID: 15016801
[TBL] [Abstract][Full Text] [Related]
8. Whole-genome cartography of p53 response elements ranked on transactivation potential.
Tebaldi T; Zaccara S; Alessandrini F; Bisio A; Ciribilli Y; Inga A
BMC Genomics; 2015 Jun; 16(1):464. PubMed ID: 26081755
[TBL] [Abstract][Full Text] [Related]
9. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
11. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines.
Shaked H; Shiff I; Kott-Gutkowski M; Siegfried Z; Haupt Y; Simon I
Cancer Res; 2008 Dec; 68(23):9671-7. PubMed ID: 19047144
[TBL] [Abstract][Full Text] [Related]
12. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
13. Microarray and ChIP-seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cells.
Zhao S; Niu F; Xu CY; Ye L; Bi GB; Chen L; Gong P; Tian G; Nie TH
Mol Med Rep; 2015 Sep; 12(3):4284-4290. PubMed ID: 26080812
[TBL] [Abstract][Full Text] [Related]
14. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.
Kiyonari S; Iimori M; Matsuoka K; Watanabe S; Morikawa-Ichinose T; Miura D; Niimi S; Saeki H; Tokunaga E; Oki E; Morita M; Kadomatsu K; Maehara Y; Kitao H
Mol Cancer Ther; 2015 Oct; 14(10):2332-42. PubMed ID: 26208523
[TBL] [Abstract][Full Text] [Related]
15. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.
Menendez D; Nguyen TA; Freudenberg JM; Mathew VJ; Anderson CW; Jothi R; Resnick MA
Nucleic Acids Res; 2013 Aug; 41(15):7286-301. PubMed ID: 23775793
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor protein p53-mediated repression of human mitotic centromere-associated kinesin gene expression is exerted via down-regulation of Sp1 level.
Jun DY; Lee JY; Park HS; Lee YH; Kim YH
PLoS One; 2017; 12(12):e0189698. PubMed ID: 29244835
[TBL] [Abstract][Full Text] [Related]
17. The mouse C/EBPdelta gene promoter is regulated by STAT3 and Sp1 transcriptional activators, chromatin remodeling and c-Myc repression.
Zhang Y; Sif S; DeWille J
J Cell Biochem; 2007 Dec; 102(5):1256-70. PubMed ID: 17471507
[TBL] [Abstract][Full Text] [Related]
18. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
19. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.
Lin RK; Wu CY; Chang JW; Juan LJ; Hsu HS; Chen CY; Lu YY; Tang YA; Yang YC; Yang PC; Wang YC
Cancer Res; 2010 Jul; 70(14):5807-17. PubMed ID: 20570896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
